Rodenbach Rachel, Caprio Thomas, Loh Kah Poh
Division of Hematology/Oncology, Department of Medicine, James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY.
Division of Geriatrics and Aging, Department of Medicine, University of Rochester, Rochester, NY.
Hematology Am Soc Hematol Educ Program. 2024 Dec 6;2024(1):340-347. doi: 10.1182/hematology.2024000560.
Despite promising advances leading to improved survival, many patients with hematologic malignancies end up dying from their underlying disease. Their end-of-life (EOL) care experience is often marked by worsening symptoms, late conversations about patient values, increased healthcare utilization, and infrequent involvement of palliative care and hospice services. There are several challenges to the delivery of high-quality EOL care that span across disease, patient, clinician, and system levels. These barriers include an unpredictable prognosis, the patient's prognostic misunderstandings and preference to focus on the immediate future, and the oncologist's hesitancy to initiate EOL conversations. Additionally, many patients with hematologic malignancies have increasing transfusion requirements at the end of life. The hospice model often does not support ongoing blood transfusions for patients, creating an additional and substantial hurdle to hospice utilization. Ultimately, patients who are transfusion-dependent and elect to enroll in hospice do so often within a limited time frame to benefit from hospice services. Strategies to overcome challenges in EOL care include encouraging repeated patient-clinician conversations that set expectations and incorporate the patient's goals and preferences and promoting multidisciplinary team collaboration in patient care. Ultimately, policy-level changes are required to improve EOL care for patients who are transfusion-dependent. Many research efforts to improve the care of patients with hematologic malignancies at the end of life are underway, including studies directed toward patients dependent on transfusions.
尽管取得了令人鼓舞的进展,提高了生存率,但许多血液系统恶性肿瘤患者最终还是死于其基础疾病。他们的临终关怀体验往往表现为症状恶化、关于患者价值观的讨论滞后、医疗保健利用率增加,以及姑息治疗和临终关怀服务参与度低。提供高质量的临终关怀面临着几个挑战,这些挑战涉及疾病、患者、临床医生和系统层面。这些障碍包括预后不可预测、患者对预后的误解以及倾向于关注近期未来,以及肿瘤学家对启动临终关怀谈话的犹豫。此外,许多血液系统恶性肿瘤患者在临终时对输血的需求不断增加。临终关怀模式通常不支持为患者持续输血,这给临终关怀的利用带来了额外的重大障碍。最终,依赖输血并选择加入临终关怀的患者往往在有限的时间内这样做,以便从临终关怀服务中受益。克服临终关怀挑战的策略包括鼓励患者与临床医生反复沟通,设定期望并纳入患者的目标和偏好,以及促进患者护理中的多学科团队协作。最终,需要政策层面的改变来改善对依赖输血患者的临终关怀。目前正在进行许多改善血液系统恶性肿瘤患者临终关怀的研究工作,包括针对依赖输血患者的研究。